Rutgers University was among a string of limited partners for the growth equity firm's ninth fund, which was oversubscribed from its $300m target.
The Rockefeller spinout will use the series C proceeds to advance two cancer drug candidates through early-stage clinical trials.
The Delft-affiliated fund has reached its first close on its way to a $120m target, having secured capital from a range of limited partners.
Université libre de Bruxelles has added a fourth Theodorus fund to its arsenal with an initial close of $23m and a target of up to $33.5m.
The UCL Technology Fund is in line for an exit from gene therapy developer Orchard Therapeutics, which has raised more than $290m in equity funding.
As MedWhat scores an initial win in its courtroom battle with Stanford, Paige.ai finds itself in the middle of allegations that its licensing deal with Sloan Kettering was improper.
Principia Biopharma, whose drug discovery platform is based on research at UCSF, has completed a $122m initial public offering after underwriters exercised their greenshoe option.
The MIT-affiliated Engine Fund has achieved a final close of more than $205m, above its initial target of $150m.